I'm not sure if people here even read the entirety of the article. From the article:<p>> We applied the AI co-scientist to assist with the prediction of drug repurposing opportunities and, with our partners, validated predictions through computational biology, expert clinician feedback, and in vitro experiments.<p>> Notably, the AI co-scientist proposed novel repurposing candidates for acute myeloid leukemia (AML). Subsequent experiments validated these proposals, confirming that the suggested drugs inhibit tumor viability at clinically relevant concentrations in multiple AML cell lines.<p>and,<p>> For this test, expert researchers instructed the AI co-scientist to explore a topic that had already been subject to novel discovery in their group, but had not yet been revealed in the public domain, namely, to explain how capsid-forming phage-inducible chromosomal islands (cf-PICIs) exist across multiple bacterial species. The AI co-scientist system independently proposed that cf-PICIs interact with diverse phage tails to expand their host range. This in silico discovery, which had been experimentally validated in the original novel laboratory experiments performed prior to use of the AI co-scientist system, are described in co-timed manuscripts (1, 2) with our collaborators at the Fleming Initiative and Imperial College London. This illustrates the value of the AI co-scientist system as an assistive technology, as it was able to leverage decades of research comprising all prior open access literature on this topic.<p>The model was able to come up with new scientific hypotheses that were tested to be correct in the lab, which is quite significant.